联系方式：400-650-8506
CNEN
产品名称 SB 269970 hydrochloride - SB 269970A
产品货号 Axon 2183 CAS [261901-57-9] MF C18H28N2O3S.HClMW 388.95 Purity: 99% Optical purity: Optically pure Soluble in water and DMSO Description Potent and selective 5-HT7 antagonist (pKi value 8.9 for 5-HT7a) with >50 fold selectivity over a wide range of serotonergic, dopaminergic and adrenergic receptors. Analogue of SB 258741 hydrochloride (Axon 1100). SB 269970 significantly blocked amphetamine and ketamine-induced hyperactivity and reversed amphetamine-induced but not ketamine-induced prepulsed inhibiton (PPI) deficits, without changing spontaneous locomotor activity and startle amplitude. References Certificates Categories Extra info P.J. Lovell et al. A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970). J. Med. Chem. 2000, 43, 342-345.    R. Galici et al. Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav. Pharmacol. 2008, 19, 153-159.  Certificate of Analysis Material Safety Data Sheet Cardiovascular Cell Signaling & Oncology CNS 5-HT7 A19 Potent and selective 5-HT7 antagonist Chemical name (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidin-1-ylsulfonyl)phenol hydrochloride Parent CAS No. [201038-74-6] Order Size Unit Price Stock 10 mg €110.00 In Stock
产品价格 现货询价，电话：010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

SB 269970 hydrochloride - SB 269970A

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 2183

CAS [261901-57-9]

MF C18H28N2O3S.HCl
MW 388.95

  • Purity: 99%
  • Optical purity: Optically pure
  • Soluble in water and DMSO

SB 269970 hydrochloride

Description

Potent and selective 5-HT7 antagonist (pKi value 8.9 for 5-HT7a) with >50 fold selectivity over a wide range of serotonergic, dopaminergic and adrenergic receptors. Analogue of SB 258741 hydrochloride (Axon 1100).
SB 269970 significantly blocked amphetamine and ketamine-induced hyperactivity and reversed amphetamine-induced but not ketamine-induced prepulsed inhibiton (PPI) deficits, without changing spontaneous locomotor activity and startle amplitude.
产品资料